Safety and Pharmacodynamic Study of CD-NP

NCT00482937 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2007-06-06

No results posted yet for this study

Summary

The primary objective of this study is to establish the safety of CD-NP in normal human volunteers.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

CD-NP

Sponsors & Collaborators

  • Nile Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482937 on ClinicalTrials.gov